Theriva Biologics reports $41.8M cash, Q4 2022 results; VCN-01 trials advance

Theriva Biologics, Inc.

Cash and equivalents $41.8M as of Dec 31, 2022, down from $67.3M; runway into Q3 2024.
G&A expenses $9.9M (+50.8% YoY); R&D expenses $11.7M (+50% YoY) driven by VCN-01 trials.
First patient dosed in VIRAGE Phase 2b trial of VCN-01 for metastatic pancreatic cancer (Jan 2023).
First patient dosed in investigator-sponsored Phase 1 trial of VCN-01 for brain tumors (Jan 2023).
SYN-004 Phase 1b/2a in allo-HCT: blinded safety/PK data presented at Tandem Meetings (Feb 2023).

item 2.02 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 0.9

Theriva Biologics, Inc. reported financial results for the fourth quarter and year ended December 31, 2022.

Period: the fourth quarter and year ended December 31, 2022
Result: reported results

Exact text from the filing

On March 30, 2023, Theriva Biologics, Inc., a Delaware corporation (the “Company”), issued a press release announcing its financial results for the fourth quarter and year ended December 31, 2022.

View on SEC.gov

8 earnings releases filed in the last 30 days. Browse all earnings releases →

Theriva Biologics, Inc. filing history →

Source: SEC EDGAR

accession 0001104659-23-038778

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.